Carlson is a Three-Time Winner of the #1 Rated Omega-3 Products Award
Arlington Heights, Ill. (March 26, 2019) – Carlson recently received the #1 Rated Omega-3 Products Award from consumerlab.com, making them a three-time winner of the prestigious award. Results are based on the 2019 consumerlab.com Survey of Supplement Users, which included nearly 11,000 participants. The survey offers consumers an opportunity to rate leading nutritional supplement brands across a variety of categories.
“We were honored to receive the #1 Rated Omega-3 Products Award from Consumer Lab for a third time,” said Carlson President Carilyn Anderson. “We take great care to source our products sustainably and responsibly – and to produce the best-tasting, highest-quality fish oils. We’re very grateful to be recognized for our efforts.”
To ensure maximum freshness, Carlson omega-3 fish oils are closely managed from sea to store. Carlson sources the highest quality, deep, cold-water fish using traditional, sustainable methods. They then go to great lengths to ensure their fish oils are pure and protected against oxidation. Carlson omega-3s are bottled or encapsulated with a touch of antioxidants and are tested by an FDA-registered laboratory for freshness, potency, and purity.
Consumerlab.com is a leading provider of independent test results and information to help consumers and healthcare professionals identify the best quality health and nutrition products. The company is privately held and has no ownership from or interest in companies that manufacture, distribute, or sell consumer products.
About Carlson Carlson began in 1965 as one woman’s mission to improve the health of families by creating nutritional supplements with high-quality ingredients. Susan Carlson’s father suffered from heart issues but found relief after taking natural-source vitamin E. Inspired by this discovery and her background as a pharmacist, Susan started Carlson out of her small Chicago apartment with a single vitamin E formula. Her product line quickly expanded. In the early 1980s, Carlson helped launch the omega-3 marketing in North America. Today, the commitment to helping families live a healthier lifestyle continues, as Susan’s daughters President Carilyn Anderson and Vice President Kirsten Carlson continue the Carlson family’s mission to produce high-quality nutritional supplements.
If you would rather not receive future communications from Carlson Labs, let us know by clicking here. Carlson Labs, 600 W University Dr, Arlington Heights, IL 60004 United States
Speed Rack Canada Returns for a Fourth Season of Celebrating the Nation’s Women Behind the Bar
The all-female speed bartending competition that raises money for breast cancer research will host the national finals of their fourth Canadian competition season in Montreal on Monday, May 13th CANADA (March 2019) -- Cocktails, competition, camaraderie - Speed Rack is back for its fourth spirited swing around Canada, as part of the organization’s eighth global competition season. The all-female speed-bartending competition has visited five Canadian cities during preliminary rounds this year, whittling down the country’s new group of top female mixologists - a uniquely impressive range of first-year bartenders to decorated mixologists and longtime bar managers - who will soon go head-to-head for the coveted title of Miss Speed Rack Canada 2019 at Les Foufounes Électriques in Montreal on May 13th. As always, the competition in Speed Rack Canada Season 4 promises to be fierce, but so does the fundraising. Co-founders Lynnette Marrero and Ivy Mix started Speed Rack in the U.S. in 2011 as a way to give back to the bar community while simultaneously providing a platform for up-and coming female bartenders. To date, Speed Rack has raised over $850,000 worldwide for breast cancer prevention, treatment and awareness. This year’s mission in Canada is no different with 100% of ticket sales being donated to Speed Rack Canada’s official charity partners, The Breast Cancer Support Fund and Breast Cancer Action Quebec. “We’re very passionate about the number of different charities that we support in cities across the world as we continue to grow, and are excited to be so close to our longtime goal of $1 million raised for charity” states Speed Rack co-founder, Lynnette Marrero. “The competition is always exciting, and we love seeing the hard work and creativity behind the bar from the Speed Rack competitors every year, but at the end of the day, our mission is to spread awareness and support research to ultimately end this disease that so many of us have been touched by in one way or another.” The fundraising is already off to a strong start with over $26,000 raised so far this season, thanks to a combined effort of proceeds from the five preliminary regional finals in Vancouver (Feb 24), Toronto (Feb 25), Calgary (March 3), Montreal (March 4), and Halifax (March 11), as well as donations from the esteemed national non-profit organization, Restaurants Canada, who partnered with Speed Rack Canada to showcase the Toronto preliminary finals during a sold-out “Industry Night Out” event on February 25th.Last year’s Speed Rack global season saw the organization’s return to Canada for a third year, as well as their much anticipated debut first season in Australia, and expansion to multiple corners of the globe. “Going into our eighth year of Speed Rack, we’re so excited to continue growing this community across the globe.” says Speed Rack co-founder, Ivy Mix. “What started out as an idea to give female bartenders a space to thrive in a male-dominated industry, has grown into this incredible network where women from around the world are able to connect and support each other both in and out of the industry, and that’s something we’re really proud to be a part of.” Every year, the community and sense of community expands - but what’s a little competition between friends? Regional winners from each preliminary round will go head-to-head during the national finals, making classic cocktails in timed heats as a panel of industry-experts judge their final execution. The star-studded cast of judges this season have included a variety of industry experts and drink writers, including Michael Hopper (Owner of Highwayman), Kate Boushel (Beverage Director at Barocco Group) and the renowned spirits expert and author, Elayne Duff who judged the Toronto preliminary competition. Industry heavyweights Kaitlyn Stewart (Diageo World Class Global Champion 2017) & Kelsey Ramage (Co-Founder of Trash Tiki) are both signed on to judge the national finals in May. Tickets for upcoming events can be procured on Speed Rack’s Website: http://events.speed-rack.com/ca/season-4. You can also follow the organization @speed_rack on Instagram and Twitter and at on Facebook at facebook.com/speedrackinfo. #backtherackABOUT SPEED RACK:Speed Rack was created and produced by nationally acclaimed bartenders and industry ambassadors, Lynnette Marrero and Ivy Mix. The first nationwide competition was designed to highlight up-and-coming women in the cocktail industry, and give back to those impacted by breast cancer, Speed Rack taps top female bartenders in leading cocktail markets and puts them head to head in timed challenges – all for the purpose of raising funds for breast cancer charities. To date, Speed Rack has raised more than $850,000 for charities supporting breast cancer research. ABOUT THE BREAST CANCER SUPPORT FUND The Breast Cancer Support Fund is a national charity managed by a volunteer board and an advisory team. Their goal is to be a change-maker among breast cancer organizations by raising awareness about the financial crisis that too often accompanies a breast cancer diagnosis and, with the support of individuals and organizations, bridge that gap between the financial reality faced by patients and the limited financial resources available. ABOUT BREAST CANCER ACTION QUEBECBreast Cancer Action Quebec is a non-profit advocacy group directed by women who have been sensitized to the trauma of breast cancer and who are committed to prevention and the reduction of the incidence of this disease. Breast Cancer Action Quebec is the only independent breast cancer organization in Canada whose mission is to work for the prevention of breast cancer and the elimination of environmental toxicants linked to the disease. ABOUT RESTAURANTS CANADA:Restaurants Canada is a growing community of 30,000 foodservice businesses, including restaurants, bars, caterers, institutions and suppliers. We connect our members from coast to coast, through services, research and advocacy for a strong and vibrant restaurant industry. Canada’s restaurant industry directly employs 1.2 million Canadians and serves 18 million customers every day. REGIONAL FINALISTS: Vancouver: Carolyn Yu - Gotham Steakhouse, BartenderAmber Bruce - Keefer Bar, Bar Manager Toronto:Colie Ehrenworth - Mahjong Bar, BartenderMarta S. - Chantecler, BartenderMonique Godinho - The Cloak Bar, BartenderAdriana Cavarra - Mother Tongue, Bartender Alberta:Christine Verdone - Milk Tiger Lounge, BartenderMaya Bartha - Bartender Quebec:Daphnee Vary - Foxy, BartenderKate Boushel - Barocco Group, Beverage DirectorTep Yith - La Distillerie, BartenderEmilie Loiselle - Cloakroom Bar, Bartender Halifax:Ellie Rideout - The Ostrich Club, BartenderMackenzie Bouchard - Middle Spoon, Bartender SPONSORS: Platinum:Lot 40 100% RyeKettle One VodkaBulleit Bourbon Bacardi Rum Johnnie Walker Black Label Jack Daniels No.7 Gold: Courvoisier CognacMartini Herradura Tequila Tequila Tromba Ungava Gin Tanqueray Gin Local:Bittered Sling BittersAlambika
Chickapea Launches High-Protein Pasta with Loblaw Stores Countrywide
COLLINGWOOD, ON (March 26, 2019) – Chickapea is thrilled to announce the launch of its high-protein pasta line into Loblaw Market stores across Canada.
Now the leading brand of pulse-based pasta in the country, Chickapea continues to make good on its mission to create good for the world through nutritious, organic meal options and impactful social contributions.
The brand’s listing with more than 330 Loblaw stores, which include Loblaws, Fortinos, Zehrs, Independent, Atlantic Superstore and more, puts Chickapea’s chickpea lentil pasta on shelves at well over 3,000 locations across North America.
“Since launching Chickapea in 2016, we have seen dramatic and exciting growth year-over-year,” said Chickapea Founder and CEO Shelby Taylor. “This expanded listing in Loblaw stores
will help us meet market demand and make it more convenient for our fans, and anyone looking for healthy versions of the foods they love, to find and enjoy our products.”
Although the business has experienced rapid growth, Taylor has ensured its positive impact every step of the way. As both a Certified Women’s Business Enterprise and Certified B Corporation, Chickapea meets the highest, measurable standards of environmental and social responsibility. The company’s vision of Good with Every Bite includes donating 3 cents from the sale of every product to feed nutritious meals to children in need, in partnership with WE Charity’s School Nutrition Program.
Chickapea’s launch with Canada’s largest supermarket chain highlights the growth and acceptance of plant-based foods and plant-based proteins in the Canadian marketplace. According to a Nielson’s study, plant-based nutrition and diet saw a 15% sales increase in 2018 which is sprouting growth for retailers.
Constantly innovating to meet the growing healthy needs of consumers, Chickapea will also be
launching spaghetti and linguini, as well as a creamy Vegan Mac in the coming weeks.
Chickapea is a nutrient-dense, high protein pasta made with only two ingredients, organic chickpeas and lentils. It is a great option for those looking for a more nutritious alternative to the comfort food they already know and love. With great taste and texture, Chickapea is a favourite for a quick, easy and nutritious meal. It’s organic, certified gluten-free, non-GMO, vegan and kosher.
Great-West Life and Dr. Joti Samra launch new tool for leaders to promote psychologically safe workplaces
WINNIPEG, March 26, 2019 /CNW/ - The Great-West Life Centre for Mental Health in the Workplace and Dr. Joti Samra announced the launch of the Psychologically Safe Leader Assessment (PSLA), a free, online tool helping assess leadership strategies related to psychological health and safety.
The assessment was developed by a team of Canadian researchers led by Dr. Joti Samra, R. Psych. – an innovator in the area of psychological health and safety in the workplace, and principal and founder of MyWorkplaceHealth.com.
The PSLA can help create a psychologically safe workplace where employees can thrive. Through the tool, leaders obtain feedback on the extent to which they implement effective strategies in five key areas:
Communication and collaboration;
Social intelligence;
Problem solving and conflict management;
Security and safety; and
Fairness and equality.
"The PSLA draws on evidence showing that employees who work for psychologically safe leaders are more likely to report higher job satisfaction and engagement, better workplace relationships, and better psychological well-being," said Dr. Samra.
"The National Standard of Canada for Psychological Health and Safety in the Workplace acknowledges the need for organizations to ensure that those in leadership roles have the training and skills to support psychological safety, and we wanted to find a way for employers and leaders to meet this requirement," said Mary Ann Baynton, Program Director for The Great-West Life Centre for Mental Health in the Workplace. "We look forward to continue building healthier workplaces through resources like the PSLA."
With the PSLA, for the first time leaders can assess the extent to which their strategies align with the National Standard of Canada for Psychological Health and Safety in the Workplace. Results from the PSLA can be supplemented by the Psychological Safe Leader Assessment: Employee Feedback (PSLA-E), allowing leaders to receive feedback from their direct reports.
To learn more about the PSLA and other resources offered by the Great-West Life Centre for Mental Health in the Workplace, visit workplacestrategiesformentalhealth.com/psla.
About the Great-West Life Centre for Mental Health in the Workplace Established in 2007, the Great-West Life Centre for Mental Health in the Workplace is a leading source of practical ideas, tools and resources designed to help with the prevention, intervention and management of workplace mental health issues. Around the world, Canada is recognized as an international leader in workplace mental health. Many individuals and organizations have contributed to this distinction and it has been a privilege for the Centre to have played a part in many of their important initiatives. For more information, visit the Centre's website at workplacestrategiesformentalhealth.com.
About The Great-West Life Assurance Company Great-West Life is a leading Canadian insurer, focused on improving the financial, physical and mental well-being of Canadians. For more than 125 years, our customers across Canada have trusted us to provide for their financial security needs and deliver on the promises we have made. Together with our subsidiaries London Life and Canada Life, we serve the financial security needs of 13 million people across Canada. To learn more, visit greatwestlife.com.
SOURCE The Great-West Life Assurance Company
CAN THE WAY YOU SIT CHANGE HOW YOU THINK?
Ergonomics Expert Shares Surprising Link Between Balance & The Brain By now you have probably heard of "active sitting." It's the latest health craze to peak the interest of sedentary Americans, especially those who work in offices. The trend blew up last summer when Apple CEO, Tim Cook announced 100% of Apple employees would be using standing desks. Since then, a whole new line of office furniture from exercise balls to treadmill desks have made their way to offices and homes across the country. But will exercise balls and standing desks really make a difference? Being more active while you sit understandably affects physical health (the more you move, the more calories you obviously burn.) but new studies show a surprising link between balance and the brain.According to new research, the way you sit not only affects physical health, it also has a dramatic impact on mental health and brain performance."The way you sit has a huge effect on brain activity. It can change anything from your mood and hormones, to memory and cognition," says ergonomics expert Scott Bahneman.Research shows that balance is the key component needed to make active sitting effective and it not only provides fitness for your body, it has a huge impact on brain activity. One of the four main classifications of fitness (along with strength, endurance, and flexibility) is balance. It is often overlooked yet it is one of the most important, and it lends itself perfectly to the office setting. Today, balance therapy is being employed in clinics to increase focus, concentration and brain health to treat conditions such as ADHD, demential, concussive head injuries and more."Balanced active sitting improves memory and cognition by requiring a complex synchronization of mental function and physical movement..." ...says Bahneman, who knows first hand the negative health consequences of sitting disease. After working at a desk job for years and experiencing a decline in health, Bahneman began researching ergonomics and made it his mission to teach others in the corporate world how to combat "sitting disease." Bahneman has fascinating information on balance therapy and the brain and has advice on how to improve brain performance congruent with physical activity. IN AN INTERVIEW / ARTICLE:The surprising link between balance and the brainFascinating information on balance therapy and why it not only helps physical health but also mental health and brain performanceHow Balanced Active Sitting can improve physical and mental healthAdvice people can use to combat sitting disease and be healthier and more active in the workplaceWhy "balance" is the key component needed to make active sitting effectiveThe impact sitting has on our overall health ABOUT SCOTT BAHNEMAN:
Scott Bahneman is an ergonomics industry expert on a mission to help people live healthier lives in the most natural way possible. He teaches others about balance therapy and other all-natural solutions to combat "sitting disease." He is the Founder & Chairman of SitTight® a company that has transformed sitting into an activity that improves your health by using your body's natural ability to balance. Bahneman been featured on Innovation Nation with Mo Rocca,Fast Company Magazine, and last year, SitTight won the bronze at the 2018 Edison Awards!More Information Visit: www.SitTight.com
Canopy Growth Receives New Health Canada Licence in Atlantic Canada That Will Boost Output, Create Jobs
New $40M production facility will increase Canopy Growth's cannabis output by more than 5,000kg annually, create more than 130 jobs in Fredericton, NB
SMITHS FALLS, ON and FREDERICTON, NB, March 25, 2019 /CNW/ - Canopy Growth Corporation (TSX: WEED), (NYSE: CGC) ("Canopy Growth" or the "Company") is pleased to announce that it has received a cultivation licence from Health Canada for its facility in Fredericton, New Brunswick. With this licensing, Canopy Growth predicts the facility will initially produce more than 5,000kg of cannabis annually, with first harvests expected to become available to the market within six months.
Developed in collaboration with Canopy Rivers Inc. (TSXV: RIV) and operating under Canopy Growth's flagship Tweed brand, the facility will support the Company's global and local operations with high quality, large-scale cannabis production capabilities that will serve the needs of recreational and medical customers. To meet that demand, Canopy Growth expects to create more than 130 jobs at the Fredericton plant.
"New Brunswick has emerged as a leader in the legal cannabis sector and the province is an excellent place to do business," said Bruce Linton, co-CEO and Chairman, Canopy Growth. "We will leverage our existing operational expertise to ensure we support the needs of our customers while making a meaningful contribution to the local economy primarily through new job creation."
Canopy Growth expects to fill a wide variety of jobs at the facility, including lab supervisors, technologists, growers, post-harvest crews, quality assurance experts, as well as shipping and maintenance crews. Their combined efforts will position the facility as one of Atlantic Canada's leading growth operations, capable of supplying the market with a steady, reliable and high-quality stream of commercial cannabis products. With distribution and strong partnerships across each of Atlantic Canada's provinces, this facility further strengthens the Company's commitment to the region.
In the coming weeks, Canopy Growth looks forward to sharing details regarding local job fairs to fill these positions. Interested applicants are encouraged to monitor canopygrowth.com/careers and the Company's Twitter feed @CanopyGrowth for more information.
Here's to Future (Maritime) Growth.
About Canopy Growth Corporation Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. Canopy Growth offers medically approved vaporizers through the Company's subsidiary, Storz & Bickel GMbH & Co. KG. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time. The Company has operations in over a dozen countries across five continents.
The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public's understanding of cannabis, and through its wholly owned subsidiary, Canopy Health Innovations ("Canopy Health"), has devoted millions of dollars toward cutting edge, commercializable research and IP development. Canopy Growth works with the Beckley Foundation and has launched Beckley Canopy Therapeutics to research and develop clinically validated cannabis-based medicines, with a strong focus on intellectual property protection. Canopy Growth acquired assets of leading hemp research company, ebbu, Inc. ("ebbu"). Intellectual Property ("IP") and R&D advancements achieved by ebbu's team apply directly to Canopy Growth's hemp and THC-rich cannabis genetic breeding program and its cannabis-infused beverage capabilities. Through partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector.
From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, Battelle, the world's largest nonprofit research and development organization, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates ten licensed cannabis production sites with over 4.3 million square feet of production capacity, including over 500,000 square feet of GMP certified production space. The Company operates Tweed retail stores in Newfoundland and Manitoba and has entered into supply agreements with every Canadian province and territory. For more information visit www.canopygrowth.com
Notice Regarding Forward Looking Statements This news release contains "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and "forward-looking information" within the meaning of applicable Canadian securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Canopy Growth or its subsidiaries to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release. Examples of such statements include statements with respect to future product format offerings. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, including the Company's ability to satisfy provincial sales contracts or provinces purchasing all cannabis allocated to them, and such risks contained in the Company's annual information form dated June 27, 2018 and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com. Although the Company believes that the assumptions and factors used in preparing the forward-looking information or forward-looking statements in this news release are reasonable, undue reliance should not be placed on such information and no assurance can be given that such events will occur in the disclosed time frames or at all. The forward-looking information and forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking information or forward-looking information to reflect new information, subsequent events or otherwise unless required by applicable securities laws.
SOURCE Canopy Growth Corporation
Twelve Canadian organizations win Employee Recommended Workplace Awards
Morneau Shepell and The Globe and Mail announce 2019 category winners at the third annual conference and award ceremony
TORONTO, March 25, 2019 /CNW/ - On March 19, Morneau Shepell and The Globe and Mail announced the category winners of the third annual Employee Recommended Workplace Award at The Globe and Mail's Solving Workplace Challenges conference in Toronto. The winning organizations achieved the top Total Health scores in their categories, representing privately owned, public, not-for-profit and government sectors in small, mid-sized and large businesses. The category winners will be profiled nationally in The Globe and Mail on Friday, March 29.
The Employee Recommended Workplace Award recognizes excellence in achieving a healthy, engaged and productive workforce, and is the only award of its kind based entirely on feedback from employees. Employees completed a short confidential survey that includes questions about their physical and mental health, as well as aspects of their work and life – all elements of Total Health that impact employee engagement and productivity. On completion, organizations received a summary report that identified areas of strength and areas where more work may be needed to improve the health of their workforce.
The 2019 Employee Recommended Workplace Award category winners are:
• Private company:
Sklar Wilton & Associates (small)
MDS Aero Support Corporation (mid-sized)
Avison Young (Canada) Inc. (large)
• Public company:
Herman Miller Canada Inc. (small)
Sandoz Canada Inc. (mid-sized)
Pason Systems Inc. (large)
• Not-for-profit:
OCAS Application Services Inc. (small)
Aéroport de Québec Inc. (mid-sized)
CAA Club Group (large)
• Government:
Town of Kentville (small)
Northwestern Health Unit (mid-sized)
NB Power (large)
"Upholding a healthy and productive workplace can be a challenging feat for employers," said Stephen Liptrap, President and Chief Executive Officer, Morneau Shepell. "Workplace stress and isolation continue to affect employees at a higher rate each year, making it significantly more difficult for employers to achieve positive total well-being of all employees. The 2019 Employee Recommended Workplace Award recipients recognize that successfully supporting the physical, mental, work and life health of employees is critical to creating a healthy workplace culture and to improving the bottom line. We are excited to honour these industry-leading companies that are paving the way for employee well-being in Canada."
"We're thrilled to see new and returning organizations represented in this year's awards. These companies are leading the way in prioritizing employee wellness," said Phillip Crawley, Publisher and Chief Executive Officer, The Globe and Mail. "We are delighted to recognize organizations that continue to uphold a high standard of employee well-being and congratulate all of the 2019 winners."
The fourth annual 2020 Employee Recommended Workplace Awards opens in early April. For more information on the awards and to register online, please visit employeerecommended.com.
About Morneau Shepell Morneau Shepell is the only human resources consulting and technology company that takes an integrated approach to employee well-being, health, benefits and retirement needs. The Company is the largest administrator of retirement and benefits plans and the largest provider of integrated absence management solutions in Canada. LifeWorks by Morneau Shepell is a total well-being solution that combines employee assistance, wellness, recognition and incentive programs. As a leader in strategic HR consulting and innovative pension design, the Company also helps clients solve complex workforce problems and provides integrated productivity, health and retirement solutions. Established in 1966, Morneau Shepell serves approximately 24,000 clients, ranging from small businesses to some of the largest corporations and associations. With more than 4,500 employees in offices worldwide, Morneau Shepell provides services to organizations around the globe. Morneau Shepell is a publicly-traded company on the Toronto Stock Exchange (TSX: MSI). For more information, visit morneaushepell.com.
About The Globe and MailThe Globe and Mail is Canada's foremost news media company, leading the national discussion and causing policy change through brave and independent journalism since 1844. With our award-winning coverage of business, politics and national affairs, The Globe and Mail newspaper reaches 6.7 million readers every week in our print or digital formats, and Report on Business magazine reaches 1.7 million readers in print and digital every issue. Our investment in innovative data science means that as the world continues to change, so does The Globe. The Globe and Mail is owned by Woodbridge, the investment arm of the Thomson family.
SOURCE Morneau Shepell Inc.
New cannabis program launches at McMaster Continuing Education
HAMILTON, ON, March 25, 2019 /CNW/ - McMaster University Continuing Education opened enrolment today for its new Science of Cannabis program – one of the first post-secondary programs in the country focused on the scientific study of cannabis and its therapeutic applications, risks and harms.
In partnership with the Peter Boris Centre for Addictions Research and the Michael G. DeGroote Centre for Medicinal Cannabis Research, the program offers an evidence-based approach to understanding the science behind the substance. As a 3-course academic certificate of completion, the program can be taken entirely online through McMaster Continuing Education and will be available to interested persons working in the health, education, public service, and social and community services sectors across the country.
Dr. James MacKillop, holder of the Peter Boris Chair in Addictions Research, Director of the Peter Boris Centre for Addictions Research, and Director of the Michael G. DeGroote Centre for Medicinal Cannabis Research, is responsible for overseeing the development of all course content and looks forward to sharing current research with participants.
"This program really takes advantage of a lot of faculty expertise," said MacKillop. "Students are going to have first-hand exposure to all different avenues of cannabis research that are being pursued within our centres."
To combat abundant misinformation about the substance, the Science of Cannabis program addresses the need for high-quality education in the field and provides students with the knowledge to separate fact from fiction.
Dr. Lorraine Carter, Director of McMaster Continuing Education, believes there is enthusiasm for the topic across a variety of sectors.
"Our goal is to offer programming that aligns with industry trends and provides skill development for working professionals," said Carter. "We know the scientific study of cannabis is something that individuals from physicians to social workers to first responders and others will be interested in. The program will help demonstrate how cannabis research interacts with fields such as addictions, mental health and public policy."
The first course, Fundamentals of Cannabis Science, will start in May 2019 and will provide a broad overview of what is known about cannabis including: the constituents of the plant, the various types of cannabis people use, pharmacology and routes of administration, effects on the body, policy in Canada, potential risks and harms, and possible therapeutic benefits. The first course will be instructed by Dr. Michael Amlung, Assistant Professor of Psychiatry at McMaster University and faculty member of the Peter Boris Centre for Addictions Research.
For more information about the Science of Cannabis program, please visit mcmastercce.ca/the-science-of-cannabis-program. McMaster Continuing Education also offers professional programming in addictions studies, health & social services, and applied clinical research. For information about all of these programs and more, visit mcmastercce.ca.
McMaster Continuing Education is one of Canada's largest and leading providers of academic certificate and diploma programs, professional development education, and corporate training. Programs are available in Business & Management, Communication & Design, Health & Social Services and Metallurgy.
SOURCE McMaster University, Centre for Continuing Education
Health Canada Approves CIMZIA® (certolizumab pegol) for Moderate-to-Severe Psoriasis
Health Canada also approves Label Updates in Pregnancy and Breastfeeding
OAKVILLE, ON, March 25, 2019 /CNW/ - UCB Canada Inc. announced today that Health Canada has approved a new indication for CIMZIA®(certolizumab pegol) for the treatment of adult patients with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy.i The approval makes CIMZIA the first Fc-free, PEGylated anti-TNF option available for the treatment of the disease where significant unmet need currently exists. UCB Canada Inc. also announced that Health Canada has approved label updates in pregnancy and breastfeeding based on two pivotal pharmacokinetic studies.ii,iii This marks a major advance for Canadian women of all ages living with plaque psoriasis and other autoimmune diseases.
"The approval of a new and effective treatment option in plaque psoriasis with demonstrated durable and flexible disease control is welcome news for Canadian patients and physicians," said Dr. Wayne Gulliver, B.Sc., B.Med.Sc., M.D., FRCPC, dermatologist and Professor of Medicine (Dermatology) at Memorial University in St. John's, Newfoundland. "CIMZIA's similar efficacy in both biologic-naïve patients and those previously treated with other biologics also helps meet an unmet need in this area."
Psoriasis is a common chronic inflammatory skin condition that impacts more than one million Canadiansiv of all ages and about 125 million people worldwide.vThere is currently no cure for psoriasis and patients may experience recurrence of symptoms throughout their life. The disease affects both men and women, with about 75 per cent of psoriasis cases in women occurring before the age of 40.vi Therefore, psoriasis may impact women during a critical time when many are planning for families.vii
"For people living with plaque psoriasis, this is a welcome new treatment option to help them manage their disease," said Kathryn Andrews-Clay, Executive Director, Canadian Association of Psoriasis Patients. "Living with psoriasis can be isolating and, at times, stressful. Combine this with balancing treatment and planning for a family, or caring for a newborn, and it can be overwhelming. We are thrilled that with CIMZIA women now have an option to control their disease at any stage of their lives – including before, during and after pregnancy."
"The approval of CIMZIA for psoriasis, and label update regarding pregnancy and breastfeeding in women with autoimmune diseases, are important treatment advances which build on more than 10 years of market experience and proven efficacy and safety," said Lionel Houle, Head of Immunology, UCB Canada Inc."Today's announcement reflects our heritage of making a difference for specific patient populations with unmet needs. Many women living with autoimmune diseases would benefit from a clearer understanding of the impact treatment can have on their baby, flare management during pregnancy and breastfeeding, and whether to restart treatment after pregnancy."
Health Canada's approval for the treatment of adult patients with moderate-to-severe plaque psoriasis (PsO) who are candidates for systemic therapy is based on data from a Phase 3 clinical development program consisting of CIMPASI-1, CIMPASI-2 and CIMPACT. The trials enrolled a total of 1,020 patients, ≥ 18 years of age of whom nearly one third had prior biologic exposure, and confirmed the durable efficacy up to 48 weeks and safety of CIMZIA in the treatment of adults with moderate-to-severe plaque psoriasis.viii Each of the three studies included an assessment of the percentage of patients who achieved at least 75% and 90% or greater disease improvement from baseline, as measured by the Psoriasis Area and Severity Index (PASI 75 and PASI 90, respectively) compared to placebo; within 16 weeks in CIMPASI-1 and CIMPASI-2, and within 12 weeks in CIMPACT. CIMPASI-1, CIMPASI-2 and CIMPACT also assessed the percentage of patients who achieved at least a two-point improvement on a five-point Physician's Global Assessment (PGA) scale to a final score representing clear or almost clear skin, each compared with placebo, at week 16. In all three trials, CIMZIA demonstrated statistically significant improvements for all primary and coprimary endpoints compared to placebo at all tested doses, and the clinical benefit was maintained through to week 48. These findings and the new approval in psoriasis that they support are significant because they build on four years of efficacy and safety data in psoriatic arthritis (PsA).
According to the updated label, the recommended dose of CIMZIA for adults with moderate-to-severe plaque psoriasis is 400 mg every other week (given as two subcutaneous injections of 200 mg each). A dose of 400 mg initially (week 0) and at Weeks 2 and 4 followed by 200 mg every 2 weeks may be considered.
About Psoriasis Psoriasis is a common chronic inflammatory skin condition. Psoriasis signs and symptoms can vary but may include red patches of skin covered with silvery scales, dry, cracked skin that may bleed and thickened, pitted or ridged nails.ix
Psoriasis affects nearly three percent of the population, or approximately 125 million people worldwide.x Symptoms vary from person to person, but for those who are more severely affected, psoriasis can have a major impact on their quality of life.xi
As many as 42% of patients with psoriasis will develop psoriatic arthritis,xii,xiii 33% will develop metabolic syndrome,[xiv] and approximately 46% are often or always depressed because of their psoriasis.xv Despite drug development advances in the past decade, patient survey data suggest that moderate-to-severe psoriasis is being undertreated.xvi
About the CIMPASI-1, CIMPASI-2 and CIMPACT Studiesxvii In CIMPASI-1 and CIMPASI-2, at week 16, the response rate for patients who achieved a PASI 75 response was 75% and 82% for patients receiving CZP 400 mg every two weeks (Q2W) and 65% and 81% for patients receiving CZP 200 mg every two weeks (Q2W), compared to 7% and 13% for patients receiving placebo, respectively. The response rate for patients who achieved a PASI 90 response was 44% and 52% for patients receiving CZP 400 mg every Q2W and 36% and 50% for patients receiving CZP 200 mg Q2W, compared to 0% and 5% for patients receiving placebo, respectively. In addition, the response rates for patients achieving at least a two-point improvement to a final score of clear or almost clear skin on the PGA scale (PGA 0/1) at week 16 was 55% and 65% for CZP 400 Q2W dose-treated subjects, and 45% and 61% for CZP 200 mg Q2W dose-treated patients, compared to 4% and 3% for subjects receiving placebo, respectively. Week 16 PASI 75 responders maintained a PASI 75 response to week 48 in 94% and 81% of patients receiving CZP 400mg Q2W, and 81% and 74% for patients receiving CZP 200 mg Q2W, respectively.
In CIMPACT, the response rate for patients who achieved a PASI 75 response at week 16 was 69% and 75% among patients receiving CZP 400 mg Q2W and CZP 200 mg Q2W, compared to 4% for patients receiving placebo, respectively. The response rate for patients who achieved a PASI 90 at week 16 was 49% and 40% among patients receiving CZP 400 mg Q2W and CZP 200 mg Q2W, compared to 0% for patients receiving placebo. In patients who received CZP 400 mg Q2W and were PASI 75 responders at week 16, 98% maintained their response at week 48. In addition, 80% of patients who received CZP 200 mg Q2W from week 16 maintained their response at week 48.
In all three trials, CIMZIA demonstrated statistically significant improvements for all primary or co-primary endpoints compared to placebo at all treatment doses, and the clinical benefit was maintained through to 48 weeks. The adverse event profile across all three trials appears consistent with the safety prole for CIMZIA in other approved indications. In the placebo- controlled portions of the clinical trials in psoriasis patients, elevated liver enzymes were reported more frequently in the CIMZIA-treated patients than in placebo-treated patients, 4.3% in the 200mg group, 2.3% in the 400mg group, and 2.5% in placebo. Additionally, cases of other psoriasis subtypes were reported (including erythrodermic, pustular, and guttate) in <1% of CIMZIA-treated patients.
About the CRIB Studyxviii CRIB was a pharmacokinetic study assessing the potential level of placental transfer of certolizumab pegol (CZP) from pregnant women to their infants. The study followed 16 women (≥ 30 weeks gestation) who were already receiving CZP at approved doses.
The study found that CZP levels were below the lower limit of quantification (LLOQ = 0.032 micrograms/ML) in 13 out of 15 infant blood samples at birth, and in all samples at weeks four and eight. One infant had a minimal CZP level of 0.042ug/ML, which was 0.09% of the mother's plasma concentration at birth. In a second infant, delivered by emergency Caesarean section, the concentration was 0.485 mcg/mL, which was 4.49% of the mother's plasma concentration at birth. At Week 4 and Week 8, all 15 infants had no measurable concentrations. No anti-CZP antibodies were detected in mothers, umbilical cords, or infants. Among 16 exposed infants, one serious adverse reaction was reported in a neonate who was treated empirically with intravenous antibiotics due to an increased white blood cell count; blood cultures were negative. These data indicate negligible to low placental transfer of CZP from mothers to infants, suggesting minimal in-utero fetal exposure during the third trimester.
About the CRADLE Studyxix The primary objectives of the CRADLE pharmacokinetic study were to determine the concentration of CZP in human breast milk and the average daily infant dose, an estimation of the daily dose of maternal CZP ingested by the breastfeeding infant.
Among 137 breast milk samples from 17 mothers, 56% had no measurable CZP; the remaining samples showed minimal levels of CZP. The median of the estimated average daily infant doses was 0.0035 mg/kg/day (range: 0 to 0.01 mg/kg/day). The percentage of the maternal dose (200 mg CIMZIA dosed once every 2 weeks), that reaches an infant ranged from 0.56% to 4.25% based on samples with measurable certolizumab pegol concentration.
In CRADLE, no serious adverse reactions were noted in the 17 infants in the study. Adverse events in mothers exposed to CZP were consistent with the known safety profile of CZP.
About CIMZIA in Canadaxx CIMZIA is the only Fc-free, PEGylated anti-TNF (Tumor Necrosis Factor). CIMZIA has a high affinity for human TNF-alpha, selectively neutralizing the pathophysiological effects of TNFalpha.
CIMZIA in combination methotrexate (MTX) is indicated for reducing signs and symptoms, inducing major clinical response, and reducing the progression of joint damage as assessed by X-ray, in adult patients with moderately-to-severely active rheumatoid arthritis (RA). CIMZIA may be used alone for reducing signs and symptoms in adult patients with moderately- to -severely active rheumatoid arthritis (RA) who do not tolerate MTX.
CIMZIA alone or in combination with MTX is indicated for reducing signs and symptoms and inhibiting the progression of structural damage as assessed by X-ray, in adult patients with moderately-to-severely active psoriatic arthritis (PsA) who have failed one or more disease-modifying anti-rheumatic drugs (DMARDs).
CIMZIA is also indicated for reducing signs and symptoms in adult patients with active ankylosing spondylitis (AS) who have had an inadequate response to conventional therapy.
CIMZIA is approved for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
About UCB Canada Inc. Inspired by patients and driven by science, UCB Canada Inc. is a biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe autoimmune and central nervous system diseases. For more information, please consult https://www.ucb-canada.ca/
References
____________________________
i CIMZIA Product Monograph. February 8, 2019
ii Mariette X, Förger F, Abraham B, et al. Lack of Placental Transfer of Certolizumab Pegol During Pregnancy: Results from CRIB, a Prospective, Postmarketing, Multicentre, Pharmacokinetic Study. Ann Rheum Dis. 2018:77(2):228-233
iii Clowse ME, Förger F, Hawng C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a Prospective, Postmarketing, Multicentre, Pharmacokinetic study. Ann Rheum Dis. 2017;76: 1890-1896
xii Mease PJ and Armstrong AW. Managing Patients with Psoriatic Disease: The Diagnosis and Pharmacologic Treatment of Psoriatic Arthritis in Patients with Psoriasis. Drugs. 2014;74(4):423-41
xiii Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features,course, and outcome. Ann Rheum Dis. 2005;64 Suppl 2:ii14-7
xiv Danielsen K, Wilsgaard T, Olsen AO, et al. Elevated odds of metabolic syndrome in psoriasis: a population-based study of age and sex differences*. British Journal of Dermatology. 2015;172:419–427
xv Weiss SC, Kimball AB, Liewehr DJ, et al. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol. 2002;47:512-518
xvi Lebwohl MG, Bachelez H, Barker J, et al. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol. 2014;70(5):871-881
xvii UCB data on file
xviii Mariette X, Förger F, Abraham B, et al. Lack of Placental Transfer of Certolizumab Pegol During Pregnancy: Results from CRIB, a Prospective, Postmarketing, Multicentre, Pharmacokinetic Study. Ann Rheum Dis. 2018:77(2):228-233
xix Clowse ME, Förger F, Hawng C, et al. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a Prospective, Postmarketing, Multicentre, Pharmacokinetic study. Ann Rheum Dis. 2017;76:1890–1896
xx CIMZIA Product Monograph. February 8, 2019
SOURCE UCB Canada Inc.
Drake’s Organic Spirits Gives Animals in Need a Second Chance
Fast-growing spirits brand funds rescue center for animals in urgent need
Minneapolis, Minnesota ( March 25, 2019 ) - – Drake’s Organic Spirits, an environmentally conscious and growing brand leading the spirits industry with its commitment to a better planet for man and beast, announced today that it will provide financial and material support to Long Lake Animal Rescue. The non-profit foundation located on 40 acres in Long Lake, MN provides a safe and loving environment for a variety of animals including horses, donkeys, dogs, cats, deer, goats and virtually any animal that needs a second chance.
Drake’s Organic Spirits produces premium organic vodka, white rum, spiced rum, Spiked Ice ice pops and organic mixes. The company’s founders, Mark and Kristen Anderson, have long had a passion for causes that support animals. It’s a passion that has been passed down to their three daughters.
“Long Lake Animal Rescue provides a life-saving home for animals who have been given up on, abused or abandoned. All they need is a second chance and unconditional love. Drake’s Organic Spirits is committed to supporting our four-legged family members who bring so much joy to our lives every day,” said Mark Anderson.
One such example is Spud, a horse at the end of his racing career. Instead of being shipped off to be slaughtered for food, he was brought to Long Lake Animal Rescue. Over the next year Spud will unwind by spending time in grass filled pastures playing with other horses. Eventually Spud will provide therapeutic relief to others by providing grooming and trail rides.
Drake’s is the first and only spirit line in the world to achieve five certifications: USDA Organic, Vegan, Gluten Free, Non GMO Project Verified and Kosher. It’s received Gold Medals at the prestigious San Diego International Spirits Competition and the Asia International Spirits Competition.
About Drake’s Organic Spirits Minneapolis-based Drake’s Organic Spirits was launched in 2017. Drake’s uses the highest quality USDA Organic and Non-GMO Project Verified ingredients to create a line of ultra- premium organic spirits. Drake’s Organic Vodka, Drake’s Organic White Rum and Drake’s Organic Spiced Rum offer a no grain, no gluten, no gmo, ultra-premium, 12 times distilled handcrafted spirits at a better price than the leading premium brands. Drake’s Organic Mixers and Organic Spiked Ice compliment their offering for adult beverages.
TRAIN IT RIGHT NEWSLETTER
Sign Up and get a free 7 day Train it Right HIIT Program!
